|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor size and GH-7 were significantly associated with biological remission and tumor relapse after GTR, respectively.
|
31368083 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Her GH level dropped to normal with a >90% decrease in tumor size, after 1-year treatment.
|
30639490 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathology and follow-up outcomes were applied as the gold standard for differentiating between 76 patients with pituitary microadenomas (38 prolactin-producing tumors, 17 adrenocorticotropic hormone adenomas and 21 growth hormone-producing tumors) and 20 patients with normal pituitary glands.
|
30944618 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup analysis was performed for patients who had biochemical or radiological "discordance"-patients who achieved biochemical remission but with incongruent insulin-like growth factor 1 (IGF-1)/GH or residual tumor on MRI.
|
31604330 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, a significantly higher expression of SSTR2 in DG compared to in SG tumors likely explains the better response of DG tumors to the normalization of growth hormone and insulin-like growth factor-1 under SA.
|
30531694 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Following surgery, pathology revealed a collision tumor; the dominant lesion was positive for GH, βTSH, βFSH, and αSU and expressed both Pit-1 and SF-1.The smaller lesion was a corticotroph tumor.
|
30610567 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly.
|
31574507 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The propofol requirement for the induction of a loss of consciousness and the achievement of a BIS of 40 is increased during the induction of general anesthesia in patients with GH-secreting tumors.
|
31035466 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silent somatotroph pituitary neuroendocrine tumors (or silent growth hormone pituitary neuroendocrine tumors, SGH-PitNET) are neoplasias with positive immunostaining for growth hormone (GH), in patients with no signs and symptoms of acromegaly nor biochemical evidence of GH hypersecretion.
|
30531696 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
E-cadherin levels are associated with GH-producing tumour histological subtypes.
|
30843342 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Pituitary tumors that cause GH excess have several variants, including pure somatotroph tumors that can be densely or sparsely granulated, or plurihormonal tumors that include mammosomatotroph, mixed somatotroph-lactotroph tumors and mature plurihomonal Pit1-lineage tumors, acidophil stem cell tumors and poorly-differentiated Pit1-lineage tumors.
|
31766255 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that MEG3 levels were positively correlated with GH and IGF-1 levels, and negatively correlated with the tumor volume of GH-secreting tumors.
|
30867789 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, to classify the different types of PA with the help of IHC, prolactin (PRL), adrenocorticotropic hormone (ACTH), and growth hormone (GH) and to predict the benign, atypical, or malignant nature of the tumor with the help of prognostic marker Ki-67.
|
27779153 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Surgical resection is the first line treatment for growth hormone (GH) secreting tumors.
|
31541405 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumour development and growth.
|
30742299 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preoperative growth hormone levels (P = 0.017), growth hormone nadir (P = 0.003), and tumor size (P = 0.026) were the most likely influencing factors associated with the surgical remission rate.
|
29360584 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior.
|
29604339 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The pre-operative mean GH level was 71.23 ± 3.29 μg/L, which was positively correlated with tumor volume (r = 0.751, P < 0.01).
|
29238923 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth hormone (GH)-producing pituitary adenomas (PAs) in childhood or young adulthood are rare, and the details surrounding these tumors remain enigmatic.
|
28849339 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite two attempts of surgical debulking of the tumour and administration of long-acting octreotide and cabergoline, growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels were uncontrolled.
|
29925553 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patient complications, resection, and remission rates were assessed.RESULTSFifty patients were eligible for this study, 15 (30%) with nonfunctional adenomas and 35 (70%) with functional adenomas, including 16 growth hormone-, 10 prolactin-, and 9 adrenocorticotropic hormone (ACTH)-secreting tumors.
|
30192191 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The data from 242 patients were evaluated, 121 with GH-secreting tumors and 121 with ACTH-secreting tumors.
|
29678528 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There was no endocrinologic remission by surgery alone for type D tumors; nevertheless, compared with type C tumors, type D tumors showed marked reductions in the postoperative nadir of GH at 1 week, 6 months, and 1 year and of insulin-like growth factor I at 1 year.
|
29906579 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified four independent predictors for the presence of an <i>AIP</i> mutation: age of onset providing an odds ratio (OR) of 14.34 for age 0-18 years, family history (OR 10.85), growth hormone excess (OR 9.74) and large tumour size (OR 4.49).
|
29440248 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Data on the association between growth hormone (GH) replacement in patients with GH deficiency (GHD) after malignancies and new neoplasms show conflicting results.
|
29228199 |
2018 |